Vincent Ossipow
Partner @ Omega Funds
Geneva, Switzerland
Vincent Ossipow is a Series A investor at Omega Funds in Geneva focused on Medical and Health Care. Vincent Ossipow is based out of Geneva, Geneve and is the Partner of Omega Funds. Vincent previously worked at BioInvent as a Board Member. Vincent Ossipow attended the University of Geneva.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Vincent Ossipow invests in
Stages Vincent Ossipow invests in
Countries Vincent Ossipow invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (40%)
- Health Care 2 (40%)
- Life Science 2 (40%)
- Biotechnology 2 (40%)
- Robotics 1 (20%)
Stage
- Series A 2 (40%)
- Seed 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
Country
- Switzerland 2 (40%)
- United States 2 (40%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M / Series A / Mar 03, 2025 | ||
| Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants. | Series A / Mar 22, 2022 | ||
| FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $10.8M / Seed / Apr 22, 2020 | ||
| Andrew Alliance is the Swiss pioneer in robotics for the Life Sciences sector. | $14M / Series C / Jun 12, 2018 | ||
| Andrew Alliance is the Swiss pioneer in robotics for the Life Sciences sector. | Series B / Aug 05, 2014 |
Co-Investors
About Omega Funds
Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.
Omega Funds Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Powell
Executive Partner
|
|||
Michael Powell
Executive Partner
|
|||
Otello Stampacchia
Founder
|
|||
|
Vincent Ossipow
Partner
|
|||
Alexia Pearsall
Chief Financial Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Vincent Ossipow invest in?
Vincent Ossipow invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vincent Ossipow?
Public channels for Vincent Ossipow include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Vincent Ossipow last invest?
The most recent investment recorded for Vincent Ossipow closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
